TheraGenetics Licenses IP from CAMH to Predict Response to Antidepressants | GenomeWeb
NEW YORK (GenomeWeb News) – Pharmacogenetic diagnostic developer TheraGenetics said today that it has licensed intellectual property from the Centre for Addiction and Mental Health in Ontario, Canada, related to predicting patient response to antidepressants.
 
TheraGenetics, which is developing a suite of tests to guide the treatment of central nervous system disorders, said that the kits will help determine whether certain patients are susceptible to side-effects from antidepressants.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.